AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 51 min read$CORT

Lyon Joseph Douglas sold $1.2M of CORT

Lyon Joseph Douglas (See Remarks) sold 10,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $116.07 ($115.40–$116.54, $1.16M total) across 3 trades over 2026-10-01 to 2026-10-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lyon Joseph Douglas
Published Oct 5, 2026, 11:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 11:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CORT
Bearish
medium confidence
Mentioned
$CORT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTBearishLow
01

Why it matters

The disclosed sale is the primary new fact; no other material news is present.

02

Market read

A modest insider sale that may cause slight short‑term pressure on CORT.

03

What to watch

Potential upcoming dilution or secondary offering that prompted the insider to reduce holdings.

Relevance 5/10Novelty 3/10Timing: post‑market filing on Oct 5

Background

Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$CORTBearishMedium confidence
Context

Officer Lyon Joseph Douglas sold 10,000 shares for $1.16M via a 10b5‑1 plan.

Expected impact

likely modest downward pressure as the market prices the insider sale.

Evidence & confidence

A $1.2M sale by an officer is material but not large enough to drive a significant move; investors may view it as a neutral to slightly negative signal.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be a routine liquidity move unrelated to company fundamentals.

Key entities

  • Company
    Corcept Therapeutics Inc.

    Biopharma listed on NASDAQ under CORT.

  • Officer
    Lyon Joseph Douglas

    Insider reporting the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CORT insider trading history →

Related articles

OCT 26
$CORTHighAI 8/10

Why is Corcept Therapeutics stock rallying today?

Corcept Therapeutics (CORT) stock rose 3.7% in pre-market trading after reporting positive Phase 2 BELLA trial results for Lifyorli in combination with nab-paclitaxel and bevacizumab in platinum-resistant ovarian cancer. The study showed improved median progression-free survival (7.2 months) and objective response rate (59%) compared to the two-drug combination. The stock had previously declined 29.6% due to competitive concerns from Genmab's trial results.

investing.com2 min
OCT 23
$CORTHighAI 8/10

Corcept Therapeutics (CORT) Shares Drop 20% on Genmab's Phase 3

Corcept Therapeutics (CORT) shares dropped 20% to $85.86 after Genmab's phase 3 trial for a competing ovarian cancer drug succeeded, raising concerns about market competition. CORT's GF Value™ suggests it is 11.2% overvalued, while its GF Score™ is 85/100, indicating strong financial health. Insiders have sold $101.5M in shares over the past year, signaling caution.

gurufocus.com3 min
OCT 23
$CORTHighAI 8/10

Why is Corcept Therapeutics stock tumbling today?

Corcept Therapeutics (CORT) shares fell 12.9% after Genmab's rival drug showed positive results in a Phase 3 trial for platinum-resistant ovarian cancer, directly competing with Corcept's Lifyorli. The decline was exacerbated by prior downgrades and market headwinds, with shares dropping from $106.05 to a low of $90.99 before partially recovering to $93.68.

investing.com2 min
SEP 22
$CORTHighAI 8/10

Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle

Corcept Therapeutics (CORT) announced that Europe's drug regulator recommended approval for its cancer therapy, relacorilant, for use with chemotherapy in platinum-resistant ovarian cancer. The recommendation is based on a Phase 3 trial showing improved patient outcomes. The European Commission's final decision is expected in Q4 2026. Corcept reported $47.6M in Q2 revenue from Lifyorli (relacorilant) and raised its full-year revenue guidance to $1.1B-$1.2B, with net income increasing to $43M.

insidermonkey.com3 min